TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: shivering threshold reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [Ca(2+)](i)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NHE‐1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual acuity improvement in amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined end-point of death and myocardial infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: mean incremental quality‐adjusted life‐years (QALYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: XAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hydration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: likelihood of high-effort choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity to expected value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response bias on the PRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delay in dyskinesia onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to levodopa initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: gain in QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Remedication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, myocardial infarction, cerebrovascular accident, target vessel failure, stent thrombosis, and binary angiographic restenosis
Endpoint domain: Mortality/survival
Primary endpoint: lower peak drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of depression and anxiety combined
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Backward stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward balance loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment effect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change scores in RDQ indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect sizes for dyspepsia and heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between physician severity ratings and RDQ scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: death-related feelings of meaninglessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: better spiritual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of discontinuation due to protocol-defined limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of discontinuation for any reason
Endpoint domain: Adverse events/effects
Primary endpoint: 50% increase in breast milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: influenza vaccination coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiopulmonary functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean maximum VAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee buckling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delayed ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACBAR of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS Compulsive subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of receiving mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of tracheostomy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: procedure expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in NPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in visual acuity by 2 or more Snellen lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive bronchial response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean maximum fall in FEV1 after montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knodell score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in communication skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain scores at rest and with coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid requirements between 24 and 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year risk of dying from lymphoma or infection
Endpoint domain: Mortality/survival
Primary endpoint: durable clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean number of voids/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk reporting by blood donors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: School days missed due to asthma
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: plaque pH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average size of the ulcer after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-statistic for biopsy performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: EASI (Eczema Area and Severity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IGA (Investigator's Global Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SCORAD (Scoring Atopic Dermatitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IKDC subjective score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of hot flushes
Endpoint domain: Adverse events/effects
Primary endpoint: increased pulse rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of attention failures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Non-high-density lipoprotein cholesterol (non-HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bothersome postoperative straining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: feeling of incomplete emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Control of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of marked recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure-free survival (FFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Complete response (CR) rate at the end of chemotherapy (CR8)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative pressure ulcer incidence category II and above
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mRS scores at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age-appropriate restraint use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypertensive blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: breast cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of care episodes resulting in ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 20-m sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported perceptions of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in average mean segment diameter per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in average minimum obstruction diameter per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: new cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life increase (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weight control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent being sedentary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D area under the curve at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: steady-state 25(OH)D increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subcutaneous fat content changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: D values for detection of vertical root fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings per patient per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of falls
Endpoint domain: Mortality/survival
Primary endpoint: Aqueous humor concentrations of fluoroquinolones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in stroke risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reduction in major vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total cost of reusable biopsy forceps
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per biopsy session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Comparison of costs between reusable and disposable biopsy forceps
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic yield of TBLB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of biopsies and procedure times
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PES
Endpoint domain: Adverse events/effects
Primary endpoint: Time taken for successful cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inadvertent carotid artery puncture rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in climacteric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of sexual life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in haemoglobin mean values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gastrointestinal intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tooth-brushing performance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total healthcare use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diastolic dysfunction prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of severe anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hb concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean ferritin concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Life (Minnesota Living with Heart Failure score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in plasma isofurans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in free hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Forced Expiratory Volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUR or BPH-related surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptom deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic efficacy of QGHXR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in alanine transaminase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: improvement in fatty liver degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in frailty and sarcopenia status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved insight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in disorganization symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical reorganization patterns in the contralateral sensorimotor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensitivity of SSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of SSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients submitting specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Deposition of lysozyme and total lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of enzyme linked fluorescent assay for endocervical swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of enzyme linked fluorescent assay for first void urine specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of enzyme linked fluorescent assay and Chlamydiazyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological disability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in serum creatinine clearance 24 hours after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Full penile rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate erections for sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean %EWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean %TWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving T2D remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adipocyte number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M2-macrophage accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extent and severity of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Eosinophil numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wakefulness/Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Decrease in serum IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in serum IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in serum IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean postoperative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Required adjustments in ventilatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete resolution of scalp psoriasis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete resolution of nail psoriasis lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: first of myocardial infarction, nonhemorrhagic stroke, heart failure, aortic valve replacement, or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: interpersonal sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Probability of local recurrence (LR)
Endpoint domain: Mortality/survival
Primary endpoint: Episodes of symptomatic vaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal preference for treatment regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost-effectiveness of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nausea rates
Endpoint domain: Adverse events/effects
Primary endpoint: Vomiting rates
Endpoint domain: Adverse events/effects
Primary endpoint: infant emergency medical care episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-min treadmill time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 to 4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: serum enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adiposity outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical health difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Photoprotective activity in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes